title: Pharmacokinetics of amifostine and its metabolites in patients.
abstract: The pharmacokinetics of the cytoprotective agent amifostine (EthyolR; WR 2721) and its main metabolites (WR 1065 and the disulphides) were studied in patients participating in two phase I trials concerning carboplatin or cisplatin in combination with amifostine. Patients were treated with a single dose or three doses of amifostine (740 or 910 mg/m2). The single or first dose was given as a 15 min i.v. infusion just before administration of the chemotherapeutic agent. The additional two infusions were administered 2 and 4 h thereafter. Amifostine was rapidly cleared from the plasma, due to, at least in part, the fast conversion into WR 1065. A biphasic decrease with a final half-life of 0.8 h was observed. The active metabolite WR 1065 was cleared from the plasma with a final half-life of 7.3 +/- 3.6 h. The short initial half-life of WR 1065 can be explained by its fast uptake in tissues and the formation of disulphides. The disulphides were cleared with a final half-life of 8.4-13.4 h and were detectable for at least 24 h after treatment. They may serve as an exchangeable pool of WR 1065. The amifostine peak values at the end of each 15 min infusion did not accumulate in the multiple dosing schedule. For WR 1065 a trend towards an increase in the peak levels was observed [C1,max: 47.5 +/- 11.9 microM, C2,max: 79.0 +/- 13.2 microM, C3,max: 84.8 +/- 15.1 microM, (n = 6)], whereas a trend towards a small decrease was observed for the peak levels of the disulphides [C1,max: 184.2 +/- 12.6 microM, C2,max: 175.0 +/- 23.7 microM, C3,max: 166.0 +/- 17.2 microM, (n = 6)]. This latter finding might suggest a saturation of the disulphide formation or a change in the uptake or elimination of WR 1065, which would result in higher WR 1065 levels in plasma and tissues, after multiple doses of amifostine.
authors.affiliation: Department of Medical Oncology, University Hospital of Vrije Universiteit, Amsterdam, The Netherlands.
authors.forename: A E
authors.initials: AE
authors.lastname: Korst
authors.forename: C M
authors.initials: CM
authors.lastname: Eeltink
authors.forename: J B
authors.initials: JB
authors.lastname: Vermorken
authors.forename: W J
authors.initials: WJ
authors.lastname: van der Vijgh
mesh_terms: D000328:Adult; D004999:Amifostine / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016190:Carboplatin / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D004220:Disulfides / Q000097:blood*; D004359:Drug Therapy, Combination; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008624:Mercaptoethylamines / Q000493:pharmacokinetics*; D008875:Middle Aged
chemical_list: D000970:Antineoplastic Agents; D004220:Disulfides; D008624:Mercaptoethylamines; C020174:N-(2-mercaptoethyl)-1,3-diaminopropane; D016190:Carboplatin; D004999:Amifostine; D002945:Cisplatin